This graphic provides a quick primer on passive immunization with HIV-specific antibodies, long-acting antiretroviral injectables, and preventive vaccines, including a new, informative table reviewing the pipelines in research and development for all three research avenues.
Selected Guide to Pipeline of Antibodies, Long-Acting ARVs and Vaccines
Px Wire April-June 2015, Vol. 8, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue, you’ll find updates and how WHO is approaching broader guidance on oral PrEP and a closer look at passive immunization.
Our centerspread provides a quick primer on passive immunization with HIV-specific antibodies, long-acting antiretroviral injectables, and preventive vaccines, including a new, informative table reviewing the pipelines in research and development for all three research avenues.
AVAC Report 2014/15: HIV Prevention on the Line
In AVAC Report 2014/15: HIV Prevention on the Line, we take on the current state of global targets for the AIDS response, looking beyond pithy slogans to explore what’s in place and what’s not in terms of targets, resources and action to begin to end the AIDS epidemic. We also provide concise updates and calls to action on key prevention interventions including AIDS vaccines, voluntary medical male circumcision, microbicides, PrEP, and hormonal contraception use and HIV risk.
Intervention Update: What’s Next for AIDS Vaccines and the P5 Partnership?
Excerpted from AVAC Report: HIV Prevention on the Line, this update details attempts to test vaccine strategy which showed promise in the RV144 trial.
What’s Next for the Pox-Protein Public-Private Partnership (P5)?
This timeline, appearing in AVAC Report 2014/2015: HIV Prevention on the Line, shows the progress and future of the P5.
An Advocate’s Guide to Tracking the P5 Development Tracks
This graphic, shown in the AVAC Report 2014/15, shows the P5 development and research track trials.
Biomedical HIV Prevention Efficacy Trials, 2014–2016
Px Wire July-September 2014, Vol. 7, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue comes out on the eve of the International AIDS Conference in Melbourne, Australia—and we begin with “AVAC’s Take” on key messages and commitments to look for at and after the meeting. We also call for more PrEP demonstration projects and provide an update of the proposed ECHO trial.
Px Wire October-December 2014, Vol. 7, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue, we offer a selective “state of the union” update on various areas of the prevention field—highlighting key developments, messages and areas of work that warrant particular joint attention at the first HIV Research for Prevention (HIV R4P) conference and beyond.
Data and Uncertainty: Understanding updates on hormonal contraceptives and HIV
AIDS 2014 featured analyses of data on the potential relationship between hormonal contraceptives and risk of HIV infection. Researchers Charles Morrison (FHI 360) and Kristin Wall (Emory University), and Mary Lyn Gaffield from the WHO discussed the newest findings and guidance.